USE CASE 01 — TRIAL SITE SELECTION
Identify high-density ART switch candidate clusters across Lesotho.
Pharma X is designing a Phase III dolutegravir formulation switch trial.
Site selection traditionally relies on facility-reported registers,
which lag 6–12 months. luma's posterior cascade gap analytics surface
active patient cohorts at district granularity, in real time.
DELIVERABLE: District-level eligible-patient posteriors (95% CI) + facility contact map.
USE CASE 02 — RWE FDA SUBMISSION
Post-market real-world effectiveness data for a generic ART regimen.
Pharma Y has launched a generic dolutegravir-based regimen in three SSA
markets and needs RWE for FDA post-market commitment. luma's adherence
and viral-suppression cascade indicators, with auditable methodology
and ministry data agreements, meet RWE-grade evidentiary requirements.
DELIVERABLE: Quarterly cohort outcomes export, CDISC-compliant.
USE CASE 03 — POST-MARKET SURVEILLANCE
Adverse event signal detection for a new long-acting injectable.
Pharma Z's long-acting cabotegravir rollout includes a post-market
safety commitment. CHW interactions surface adherence challenges, side
effect patterns, and discontinuation reasons in near-real time —
classifiable downstream signals well before facility registers report.
DELIVERABLE: Weekly safety signal digest + drill-down API access.
USE CASE 04 — PORTFOLIO PRIORITIZATION
Burden-of-disease comparison across SSA markets for a TB pipeline.
Pharma W's TB R&D portfolio needs market sizing across multiple SSA
countries. luma's regional aggregation (multi-country, on roadmap)
provides comparable burden estimates with consistent methodology —
replacing the patchwork of WHO Global TB Reports + UNAIDS estimates +
bilateral DHS feeds that pharma teams currently triangulate manually.
DELIVERABLE: Cross-country burden comparison dashboard + API.